Longeveron (LGVN) Return on Sales Growth (3y) (2023 - 2026)

Longeveron (LGVN) Return on Sales Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 1.00
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 0.00
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 0.00
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 0.00
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Longeveron 15.18 Bn 15.16 Bn 264,000.00 139.00

Historic Data

Download Data
DateValue
Mar 31, 2026 139.00
Dec 31, 2025 26.00
Sep 30, 2025 -10.00
Jun 30, 2025 -11.00
Mar 31, 2025 -4.00
Dec 31, 2024 -224.00
Sep 30, 2024 92.00
Jun 30, 2024 33.00
Mar 31, 2024 44.00
Dec 31, 2023 -86.00
Sep 30, 2023 -35.00
Jun 30, 2023 -23.00
Mar 31, 2023 -153.00